RecruitingPhase 3NCT06834100
Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
Simple Blinded Multicenter Randomized Comparative Study to Assess Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE
Sponsor
NPO Petrovax
Enrollment
240 participants
Start Date
Feb 12, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug
Eligibility
Min Age: 3 YearsMax Age: 55 Years
Inclusion Criteria7
- Male and female subjects aged 3-55 years old inclusive at the time of screening beginning.
- Availability of a signed Volunteer Informed Consent Form (Volunteer Information Sheet, VIS) (for participants aged 7-55 years inclusive) and/or the parent/adoptive parent informed consent form (Parent Information Sheet, PIS) signed by one of parents/adoptive parents (for participants aged 3-17 years old inclusive).
- Negative result of SARS-CoV-2 antigen rapid test at screening.
- Negative pregnancy test result in fertile females of reproductive age. For females not reached puberty, and for girls/women unable to childbirth (with past infertility, hysterectomy, bilateral oophorectomy, bilateral tubal ligation, menopause for more than 2 years), the pregnancy test shall not be performed.
- For participants of 14-55 years old inclusive with preserved reproductive function, the consent to use of reliable methods of contraception (abstinence, condoms in combination with spermicide and/or hormonal contraception) during the study.
- For participants aged 3-13 years old inclusive and females incapable of childbearing, the consent to use reliable methods of contraception is not required.
- The consent of a participant and/or a parent/an adoptive parent of a participant to cooperate in good faith with the investigator and the center staff, come to appointed visits, fill out the observation diary and comply with the requirements of the Protocol.
Exclusion Criteria24
- Hypersensitivity to any component of the test/reference drug.
- Evident severe systemic reactions to any vaccines in anamnesis.
- Impossibility of intramuscular injections.
- Changes in the skin (pigmentation, tattoo, scars etc.) at the planned injection site of the test/reference drug (the deltoid muscle area).
- Acute infectious and non-infectious diseases, exacerbation of chronic diseases at screening or less than 14 days before screening.
- Body temperature measured in the armpit ≥ 37.0°C at Visits 0 and 1.
- The history of chronic diseases that are significant in the opinion of the investigator (for example, malignant neoplasms, blood diseases, autoimmune diseases, immunodeficiencies, etc.).
- The history of meningococcal infection.
- Contact with a person with the confirmed infection caused by N. meningitidis less than 2 months before screening.
- The history of convulsive syndrome or the advanced neurological disease.
- The history of Guillain-Barré syndrome.
- The history of mental diseases.
- Drug administration:
- the history of meningococcal mono- or polyvalent vaccine, influenza vaccine within 14 days before screening, other vaccines within 30 days before screening;
- immunostimulants less than 30 days before screening;
- the immunosuppressive therapy, including systemic corticosteroids, prescribed for more than 5 days, or in the daily dose of more than 1 mg/kg/day of prednisolone or its equivalent - less than 30 days before screening;
- antipyretics, analgesics - for less than 24 hours before Visits 0 and 1;
- systemic antibacterial drugs-- for less than 72 hours before Visits 0 and 1;
- anticoagulants - for less than 3 weeks before Visits 0 and 1;
- immunoglobulins, blood or plasma products - for less than 3 months before Visits 0 and 1.
- Planning the administration of vaccines with the exception of the test/reference drug during the clinical study.
- Surgical interventions performed less than 3 months before screening.
- Participation in another clinical study less than 30 days before screening.
- Other conditions that, in the opinion of the investigator, interfere to the enrollment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGpolysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y
Group 1 (n = 40) will receive GNG-DE at a dose of 0.5 mL intramuscularly into the deltoid site. Group 2 (n = 40) will receive Menactra® at a dose of 0.5 mL intramuscularly into the deltoid site.
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06834100
Related Trials
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
NCT000061501 location
Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa
NCT058814471 location
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
NCT009677851 location
Collection of Blood Samples for New Diagnostic Devices 2
NCT055689667 locations
Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)
NCT057706224 locations